[HTML] frontiersin.org

[HTML][HTML] Immunotherapy for hepatocellular carcinoma: current status and future prospects

Z Liu, X Liu, J Liang, Y Liu, X Hou, M Zhang… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …
被引用次数：97 相关文章

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.

Z Liu, X Liu, J Liang, Y Liu, X Hou, M Zhang… - Frontiers in …, 2021 - europepmc.org
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …
[HTML] nih.gov

[HTML][HTML] Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Z Liu, X Liu, J Liang, Y Liu, X Hou, M Zhang… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Z Liu, X Liu, J Liang, Y Liu, X Hou… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Z Liu, X Liu, J Liang, Y Liu, X Hou… - Emerging …, 2022 - books.google.com
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …